Fig 1: Heterozygous LARS1 deficiency mitigates UUO-induced kidney fibrosis. A and B: The levels of 24-h urinary protein content, BUN, SCr, β2-MG, and Cystatin C at day 7 following UUO in Lars1+/− mice (n = 5 per group). C: Masson’s trichrome and immunohistochemical staining in kidney sections at day 7 following UUO in Lars1+/−mice (n = 5 per group). Scale bar,100 μm. D: Immunoblotting analysis of FN, Collagen I, Vimentin, α-SMA, and E-Cadherin in the kidneys at day 7 following UUO and subjected to quantitative analysis. (n = 3 per group). E: Immunofluorescence of LARS1 (red) and E-Cadherin (green) at day 7 following UUO. Scale bar, 25 μm. F: Immunofluorescence of LARS1 (green) and α-SMA (red) at day 7 following UUO. Scale bar, 25 μm. Data are shown as means ± SD. *P < 0.05, **P < 0.01